Now showing items 1-6 of 6

    • ADGRL4/ELTD1 Silencing in Endothelial Cells Induces ACLY and SLC25A1 and Alters the Cellular Metabolic Profile. 

      Favara, DM; Zois, CE; Haider, S; Pires, E; Sheldon, H; McCullagh, J; Banham, AH; Harris, AL (2019-11-25)
      Adhesion G Protein-Coupled Receptor L4 (ADGRL4/ELTD1) is an endothelial cell adhesion G protein-coupled receptor (aGPCR) which regulates physiological and tumour angiogenesis, providing an attractive target for anti-cancer ...
    • Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer. 

      Morotti, M; Bridges, E; Valli, A; Choudhry, H; Sheldon, H; Wigfield, S; Gray, N; Zois, CE; Grimm, F; Jones, D; Teoh, EJ; Cheng, W-C; Lord, S; Anastasiou, D; Haider, S; McIntyre, A; Goberdhan, DCI; Buffa, F; Harris, AL
      Tumor hypoxia is associated with poor patient outcomes in estrogen receptor-α-positive (ERα<sup>+</sup>) breast cancer. Hypoxia is known to affect tumor growth by reprogramming metabolism and regulating amino acid (AA) ...
    • IGF-1R associates with adverse outcomes after radical radiotherapy for prostate cancer. 

      Aleksic, T; Verrill, C; Bryant, RJ; Han, C; Worrall, AR; Brureau, L; Larré, S; Higgins, GS; Fazal, F; Sabbagh, A; Haider, S; Buffa, FM; Cole, D; Macaulay, VM
      Background Activated type 1 insulin-like growth factor receptors (IGF-1Rs) undergo internalisation and nuclear translocation, promoting cell survival. We previously reported that IGF-1R inhibition delays DNA damage repair, ...
    • Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer. 

      Lord, SR; Cheng, W-C; Liu, D; Gaude, E; Haider, S; Metcalf, T; Patel, N; Teoh, EJ; Gleeson, F; Bradley, K; Wigfield, S; Zois, C; McGowan, DR; Ah-See, M-L; Thompson, AM; Sharma, A; Bidaut, L; Pollak, M; Roy, PG; Karpe, F; James, T; English, R; Adams, RF; Campo, L; Ayers, L; Snell, C; Roxanis, I; Frezza, C; Fenwick, JD; Buffa, FM; Harris, AL
      Late-phase clinical trials investigating metformin as a cancer therapy are underway. However, there remains controversy as to the mode of action of metformin in tumors at clinical doses. We conducted a clinical study ...
    • Landscape of transcriptomic interactions between breast cancer and its microenvironment. 

      Fox, NS; Haider, S; Harris, AL; Boutros, PC (2019-07-15)
      Solid tumours comprise mixtures of tumour cells (TCs) and tumour-adjacent cells (TACs), and the intricate interconnections between these diverse populations shape the tumour's microenvironment. Despite this complexity, ...
    • Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin. 

      Lord, SR; Collins, JM; Cheng, W-C; Haider, S; Wigfield, S; Gaude, E; Fielding, BA; Pinnick, KE; Harjes, U; Segaran, A; Jha, P; Hoefler, G; Pollak, MN; Thompson, AM; Roy, PG; English, R; Adams, RF; Frezza, C; Buffa, FM; Karpe, F; Harris, AL
      Background Epidemiological studies suggest that metformin may reduce the incidence of cancer in patients with diabetes and multiple late phase clinical trials assessing the potential of repurposing this drug are underway. ...